Project
SAKK HOVON 135
Ongoing - recruitment closed · 2016 until 2099
Früh Martin, Harder Anja, Müller Fiona
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2016
End Date
2099
Financing
SAKK
Labels
leukemia
Brief description/objective
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged ≥ 66 years.